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Background: In France, it is recommended that girls and women aged 14–23 are vaccinated against the human
papillomavirus (HPV). However, French women’s knowledge of and attitude towards the vaccine has been little
studied.
Methods: Thirty-nine general practitioners, representative of those working in the large Rhône-Alpes region, offered
a self-administered questionnaire on cervical cancer (CC) prevention to all 18–65 year-old women who came for
consultation during June and July 2008. In addition, semi-structured interviews were undertaken with a sample of
those who had daughters aged 14–18.
Results: Of the 1,478 women who completed the questionnaire, only 16.9% mentioned HPV as the cause of CC,
even though 76.2% knew of the vaccine. 210 women had daughters aged 14–18, and 32 were interviewed.
Compared with the wider group, more of these women were aware of the HPV vaccine (91.4%). 44.8% knew the
target population and 17.1% the recommended ages for vaccination. 54.3% favoured HPV vaccination; 37.2% were
undecided and only 0.9% were opposed. The main barrier to acceptance was the recency of the vaccine’s
introduction and concern about possible side effects (54.9%); 14.1% preferred to rely on their GP’s decision. Factors
associated with acceptance of the HPV vaccine were having previously vaccinated a child against pneumococcus
(OR=3.28 [1.32-8.11]) and knowing the target population for HPV vaccination (OR=2.12 [1.15-3.90]). Knowing the
recommended frequency of Papanicolaou smear testing (Pap test) screening was associated with lower acceptance
(OR=0.32 [0.13-0.82]).
Conclusions: Few mothers are opposed to HPV vaccination. Factors associated with acceptability were knowledge
about the vaccine, acceptance of other vaccines and, unexpectedly, lack of knowledge about the recommended
frequency of Pap testing. On multivariate analysis, compliance with recommendations for Pap test screening and
socioeconomic factors had no effect on views about HPV vaccination. Given that concern about possible side
effects is the major barrier to wider acceptance of the HPV vaccine in France, GPs have a key role in providing
information.
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Cervical cancer (CC) is the tenth most common cancer
among French women [1]. In 2011, an estimated 2,800
new cases were diagnosed, leading to 1,000 deaths [1].
The fight against CC involves two strategies: Papanico-
laou smear testing (Pap test), and vaccination against the
sexually transmitted Human Papillomavirus (HPV) re-
sponsible for nearly all cases of CC [2]. In France, Pap
test screening is recommended every 3 years for women
aged 25–65 [3] and its use since the 1970s has markedly
decreased CC incidence (2.9% decrease per year between
1980 and 2005) and mortality (4.0% decrease per year).
Nevertheless, adherence with Pap test screening recom-
mendations is still insufficient: in the period 2006–2008,
it was estimated that only 56.6% of 25–65 year old
women had had the smear within the previous three
years [3]. There are also major geographical and socio-
economic disparities in take-up rate [4].
More recently, a new primary prevention tool has be-
come available with the development of two vaccines
[5;6] targeting the high-risk HPV 16 and 18 genotypes
responsible for 70% of CC [2]. These vaccines were li-
censed in France in 2007 and their use is funded. French
health authorities recommended HPV vaccination for
girls reaching 14 years with catch-up vaccination for
girls aged 15–23 within their first year of sexual activity
[5]. Since parental consent is required for vaccination of
adolescent girls, parents, and especially mothers, are key
decision-makers and potentially a major source of infor-
mation for their daughters [6].
Attitudes towards this new vaccine seem to be posi-
tive, with most studies on parental attitudes reporting
acceptance rates above 60% [7-11]. Nevertheless, aware-
ness about CC and HPV among women is limited [12].
Factors associated with the decision to vaccinate are
complex and varied. Previous studies highlighted con-
cerns about safety, but evidence on the influence of
parental knowledge [10,13-15], the preventive health
practices of the mother [8,13,16] and socio-cultural
context [8,10,11,17,18] is conflicting. In a recent meta-
analysis of studies dealing with parental attitudes to-
wards HPV vaccination, Trim et al. showed that being
concerned about the potential risk of cancer and be-
lieving their daughters might contract HPV and related
diseases were drivers for HPV vaccination [19]. How-
ever, parents would prefer to vaccinate older children
and those who were sexually active. Previous attitudes
towards other vaccines predicted acceptance of HPV vac-
cination, and a physician’s recommendation was also a
major factor. In addition, because HPV is sexually trans-
mitted, parental acceptance of the vaccine raises issues,
including the perceived risk of promoting risky sexual
behaviour [19,20], which are broader and quite distinct
from those raised by other vaccines [21].Most previously published studies on CC and HPV
awareness have been from North America: with the ex-
ception of the United Kingdom, little such research has
been carried out in Europe [19]. Several factors specific
to France make it a particularly interesting case study of
attitudes towards and uptake of HPV vaccination. First,
the target age for immunization (14 years and above) is
relatively old compared with that in other countries. Sec-
ondly, the controversy in the 1990s over the supposed
link between the vaccination of adolescents against
hepatitis B and the development of multiple sclerosis
was sufficient to bring a halt to the immunization cam-
paign. This particular scare about vaccination did not
occur in other countries but may have had long-term
effects on the perceived safety of mass vaccination in
France. Such a finding would have wide implications. Fi-
nally, the fact that national regulators recommend HPV
vaccination and the 65% reimbursement of costs could
provide a favourable setting.
The first objective of this study, which combined
quantitative and qualitative techniques, was to assess
knowledge about CC, the Pap test and HPV vaccination
in 18–65 year-old French women one year after the
introduction of the vaccine. The second objective was to
assess mothers’ acceptance of HPV vaccination for their
14–18 year old daughters and determinants of that ac-
ceptability. The age range 14–18 was chosen to en-
compass girls above the age at which vaccination is
recommended in France and below the age at which
they can themselves legally assent to the procedure. This
study was part of the REMPAR (Recherche et Evaluation
des Moyens de Prévention Anti-HPV en Rhône-Alpes)
programme aimed at evaluating means of preventing
HPV-mediated disease.
Methods
This cross-sectional study, conducted in the Rhône-
Alpes region of France in June and July 2008, used both
quantitative (self-administered questionnaire) and quali-
tative methods (semi-structured interviews).
Population
The study population was women aged 18–65 living in
the Rhône-Alpes region who visited a participating gen-
eral practitioner (GP) within the two months specified
above, without exclusion criteria. Participants were con-
secutively recruited by GPs during a consultation (which
can have been for any reason). The 39 physicians who
agreed to participate were volunteers from a sample of
279 GPs who took part in an earlier study [22]. They
were representative in gender, location and the nature of
their practice of GPs in the Rhône-Alpes. This region
has 6 million inhabitants and comprises 10% of the
French population.
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GPs offered the self-administered questionnaire to all
women who met the inclusion criteria (There were no
exclusion criteria.). The anonymous questionnaire had
five parts: 1) socio-demographic data (age, place of resi-
dence, occupation, educational level, marital status,
number, age and gender of children), 2) practices related
to disease prevention (immunization for themselves and
their children, tobacco consumption), 3) gynaecological
history (surgery, sexually transmitted diseases, history of
Pap test screening and any abnormal findings), 4) know-
ledge about CC including its cause, the role of HPV, CC
prevention (the role of the Pap test and HPV immu-
nization) and 5) the acceptability of HPV vaccination.
Questions on socio-demographic variables, preventive
health practices and gynaecological history were multiple-
choice. Questions on knowledge were multiple-choice in
relation to the Pap test and open-ended with regard to
the cause of CC and understanding of HPV vaccination.
Answers to open-ended questions were recoded accord-
ing to predefined categories. The acceptability of HPV
vaccination was assessed by asking respondents to
choose a single response from six options (Table 1).
Based on their answer, respondents were classified as
favourable, undecided or opposed to HPV vaccination.
The comprehensibility of the questionnaire was validated
before its use in the survey through a pilot study involv-
ing three focus groups of 12 women each from low,
medium and high socio-economic groups).
Qualitative data
Women completing the questionnaire who had daugh-
ters aged 14–18 were also asked if they would volunteer
to take part in a semi-structured, face to face interview
conducted in their own home by a sociologist. It was
thought particularly important to understand the opi-
nions, and the reasons underlying them, of mothers from
an underprivileged, lower socioeconomic background,
and of women whose questionnaire responses showed
them to be opposed to HPV vaccination. Among the vol-
unteers, selection for interview was designed to includeTable 1 Acceptability of HPV vaccination: options
presented in the self-administered questionnaire, and the
coding of responses
About this vaccination against cervical cancer, if you have a
daughter
1. I will get some information and consider it Undecided
2. I prefer to wait Undecided
3. She(they) is(are) already vaccinated Favourable
4. I intend to vaccinate my daughter(s) in the future Favourable
5. I will vaccinate my daughter(s) if she(they) asks me Undecided
6. I think that this vaccination is useless Opposeda high proportion of mothers from both groups. Inter-
views explored in greater depth topics covered in the
questionnaire, notably gynaecological, history, practices
related to disease prevention, women’s understanding of
HPV vaccination, and factors related to its acceptability.
There was particular emphasis on the latter, given our
concern to better understand the drivers of and barriers
to acceptance. Interviews lasted 30 to 60 min, were
audio-taped and were transcribed verbatim. A content
analysis was carried out using an analysis grid designed
to build on the topics addressed in the quantitative part
of the study and explore them in greater depth. The
results were then compared with analysis using specific
software, NVivo (QSR International) according to the
methodology proposed by Miles & Huberman [23].
Statistical analysis
Descriptive data were calculated for the survey popula-
tion as a whole and for the subgroup composed of
mothers of one or more 14–18 year old girls. The rela-
tionship between mothers’ views (favourable versus un-
decided or opposed) and potential predictive factors was
studied using Chi-square or Fisher's exact test for quali-
tative variables and using Student’s t or Mann–Whitney
U test for quantitative variables. A stepwise backward lo-
gistic regression was used to determine the most suitable
model for multivariate analysis. Variables with a p value
≤ 0.20 in univariate analysis were entered in the model
and a p value ≤ 0.05 was considered statistically signifi-
cant. Data analysis was performed using the SAS 9.1
software (SAS Institute, Cary, NC).
Ethics
This study was approved by the French National Com-
mittees for personal data protection in medical research
and conformed to the Declaration of Helsinki.
Results
The population studied
A total of 1,478 women completed the questionnaire:
702 (47.5%) were 18–39 years old and 776 (52.5%) aged
40–65 years. This age distribution is similar to that for
the Rhône-Alpes region as a whole, for which the corre-
sponding figures are 47.2% and 52.8% (p=0.81). Among
these women, 210 (14.2%) had one or more daughters
aged between 14 and 18 at the time of the study. Of
these mothers, 32 were interviewed.
The socio-demographic characteristics, immunization
status and gynaecological history of the study population
as a whole and of the subgroup with daughters of vaccin-
ation age are given in Table 2. The mean (+/− SD) age for
respondents overall was 40.5 +/− 12 years and 43.5 +/− 4.4
for the subgroup of mothers of teenage girls (in which,
understandably, 40–49 year olds were over-represented).
Table 2 Sociodemographic characteristics, vaccination status and gynaecological history of women as a whole and of
mothers of 14–18 year old daughters
Characteristic Whole population Mothers of a 14–18 yr old daughter Interviewed mothers
N (%) (N=1,478) (N=210) (N=32)
Age (years)
18-29 309 (20.9) - -
30-39 393 (26.6) 40 (19.1) 9 (28.1)
40-49 414 (28.0) 150 (71.4) 21 (65.6)
50-65 362 (24.5) 20 (9.5) 2 (6.3)
Employment
In employment 942 (69.6) 159 (79.5) 17 (53.2)
Unemployed/Housewife/Retired 411 (30.7) 41 (20.5) 15 (46.9)
Educational level
Studies ongoing 100 (7.5) 1 (0.5) -
Lower secondary 540 (40.6) 99 (52.1) 24 (75.0)
Upper secondary, non tertiary 606 (45.6) 81 (42.6) 8 (25.0)
Tertiary 83 (6.2) 8 (4.2) -
Social/financial assistance1 67 (4.9) 6 (3.1) 5 (15.6)
Marital status
Married/Living with a partner 1034 (70.5) 178 (86.0) 22 (68.8)
Single/Divorced/Widowed 431 (29.5) 29 (14.0) 10 (31.3)
Vaccination status themselves
Diphtheria-Tetanus-Poliomyelitis and BCG 1376 (93.1) 200 (95.2) 32 (100.0)
Measles, Mumps and Rubella 714 (48.3) 86 (40.9) 9 (28.1)
Hepatitis B 754 (51.0) 74 (35.2) 11 (34.4)
Vaccination status of their children2
Diphtheria-tetanus-poliomyelitis and BCG vaccine 1 096 (96.1) 205 (97.6) 32 (100.0)
Measles, Mumps and Rubella 837 (73.4) 172 (81.9) 21 (65.6)
Chickenpox 108 (9.5) 20 (9.5) 2 (6.3)
Rotavirus 10 (0.9) 0 (0.0) -
Pneumococcus 257 (22.5) 38 (18.1) 5 (15.6)
Hepatitis B 568 (49.8) 103 (51.8) 16 (50.0)
Current cigarette smoker 248 (16.8) 33 (16.6) 6 (18.8)
Usual frequency of gynaecologic follow-up
Each year 907 (63.6) 144 (70.6) 18 (56.3)
Every 2–3 years 305 (21.4) 38 (18.6) 7 (21.9)
Less than every 2–3 years/Never 213 (14.9) 22 (10.8) 7 (21.9)
Pap test within the last 3 years 1186 (82.9) 180 (87.0) 26 (81.3)
History of abnormal Pap test 147 (9.9) 27 (13.1) 4 (12.5)
Gynaecologic surgery 161 (10.9) 21 (10.7) 3 (9.4)
Sexually transmitted diseases 86 (5.8) 17 (8.1) 2 (6.3)
1In receipt of free health insurance or financial assistance.
2N= 1140 women who had at least one child.
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mothers compared with 51% for the sample as a whole),
which was attributable to their age distribution, there were
few differences in vaccination status, demographics or
gynaecological history between the subgroup with daugh-
ters of vaccination age and respondents as a whole.Knowledge about CC and its prevention
Among the 1,478 respondents as a whole, knowledge
about the Pap test was quite good (61% knew its role),
and better than that about the causes of CC: only 16.9%
of women mentioned HPV in this context. However, the
question on the causes of CC was open-ended while that
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HPV vaccine was high (76.2%) but the recommended
target population and age for vaccination were not pre-
cisely known (Table 3). The media were the respondents’
major source of information on HPV vaccination: 54.7%
of women had heard of the vaccine through television
while only 16.0% said they had been informed about the
vaccine by their physician.
Knowledge about the Pap test among mothers of
14–18 year old daughters was not different from that
of the wider population of women surveyed (65.2% vs
61.0% knew its role). As with the wider sample, relatively
few mothers of teenage girls mentioned HPV as a causeTable 3 Knowledge about cervical cancer and its prevention a
Question
What is the role of the Pap test? 1
Answer correct : to prevent CC
Incorrect: to treat CC, to prevent all gynaecologic cancers, to check the ov
No information/No response
When should a woman have a Pap test? 1
During her whole adult life
Incorrect : before or after the menopause
No information/No response
How often should she have a Pap test? 1
Every 2–3 years (French national recommendation)
Yearly
Incorrect : once or from time to time
No information/No response
What is the cause of CC?2
HPV
Related response (STD, viral infection)
Incorrect cause mentioned
No information/No response
Have you ever heard of HPV vaccination? 1
Yes
Who should be vaccinated?2




At which age is vaccination recommended?2
14 -23
Answer close to recommendation: (14–23 +/− 4 years)
Incorrect
No information/No response
CC, Cervical cancer, Pap test, Papanicolaou smear test, HPV, Human papillomavirus.
1Multiple Choice Question.
2recoded open-ended question.
3reply included only one of the two concepts: young girls or before/within the firstof CC (20.9% vs 16.9%). However, during the interview,
without multiple-choice options, mothers had more dif-
ficulties than the wider group in explaining the role of
Pap testing: many said “It is for prevention” without spe-
cifying the disease that was being prevented. The
mothers who knew about HPV in the interview were
mainly those who had already vaccinated their daugh-
ters. These women had also had the situation explained
by their GPs before vaccination. Even so, many were not
clear about the link between HPV infection and CC. All
but one of the 32 mothers interviewed (91.4%) knew
about the HPV vaccine. As in the wider population of
women, mothers had heard of this vaccine mainlymong women and mothers of 14–18 year-old daughters
Whole population Mothers of a 14–18 yr old daughter
(N=1,478) (N=210)
901 (61.0) 137 (65.2)
aries 338 (22.8) 50 (23.9)
239 (16.2) 23 (10.9)
1 211 (81.9) 178 (84.8)
87 (5.9) 10 (4.8)
180 (12.2) 22 (10.4)
590 (39.9) 112 (53.3)
795 (53.8) 91 (43.3)
18 (1.2) 0 (0.0)
75 (5.1) 7 (3.3)
251 (16.9) 44 (20.9)
120 (8.1) 22 (10.5)
23 (1.5) 11 (5.2)
1084 (73.3) 133 (63.3)
1127 (76.2) 192 (91.4)
327 (22.1) 64 (44.8)
220 (14.9) 30 (14.2)
447 (30.2) 82 (39.0)
484 (32.8) 34 (16.2)
180 (12.2) 36 (17.1)
612 (41.4) 91 (43.3)
135 (9.1) 40 (19.0)
551 (37.3) 43 (20.5)
year after the first intercourse.
Haesebaert et al. BMC Public Health 2012, 12:1034 Page 6 of 10
http://www.biomedcentral.com/1471-2458/12/1034through television (56.2%), but a greater proportion
(39.1% vs 16.0% for respondents as a whole) had had in-
formation from their physicians.
Despite this, more than a half of the mothers did not
know the target population or the precise recommended
ages for vaccination (although most responses such as
“young women” and “adolescents” were broadly correct).
In interviews, they explained “It is for teenagers”, without
mentioning ages. They knew from their physicians who
should be vaccinated “My physician told me that this
concerned my daughter”, because of her age and sexual
history. However, few mothers had a detailed recollec-
tion of the information provided.
Acceptability of the HPV vaccine among mothers of
14–18 year old daughters
Among the 210 mothers who completed the question-
naire, 194 responded to the question regarding HPV
vaccine acceptability: 2 were opposed (1.0%), 78 were un-
decided (40.2%) and 114 were favourable (58.8%). A total
of 46.4% had already vaccinated their daughters (Table 4).
Among the 32 mothers interviewed, 2 were opposed to
the vaccine, 8 were undecided and 22 were favourable.
The latter group included the 13 who had already vacci-
nated their daughters.
The major reason given in interviews by favourably
disposed mothers (and cited by 65.8%) was that vaccin-
ation offered the opportunity of preventing a severe and
potentially fatal disease, namely CC, in their daughters.
The perceived danger of CC was frequently mentioned
as driving the decision to vaccinate. Mothers mentioned
the “fear of cancer” and their wish to “protect (their)
child”. One explained: “I don’t want my daughter to tell
me ‘I have a cervical cancer’ while a vaccine exists”. The
second most frequent reason for vaccination (reported
by 10% in questionnaires and 40% in interviews) was the
favourable opinion of the physician. Those interviewed
explained that physicians reassured them if they had any
questions: “She recommends it. I think I can trust her.
She told me if she had a daughter of this age, she wouldTable 4 HPV vaccine acceptability among mothers of
14–18 year old daughters (N=210)
Position N (%)
Favourable 114 (54.3)
My daughter(s) is/are already vaccinated 53 (25.2)
I intend to vaccinate my daughter(s) in the future 61 (29.1)
Unfavourable (Undecided/Opposed) 80 (38.1)
I will get some information and consider it 41 (19.5)
I prefer to wait 22 (10.5)
I will vaccinate my daughter(s) if she(they) asks me 15 (7.1)
I think that this vaccination is useless 2 (0.95)
Missing data 16 (7.6)vaccinate her against HPV.” Nevertheless, in the ques-
tionnaires, 14.4% of favourably disposed mothers men-
tioned incorrect expectations of the vaccine such that it
would eradicate risk of all gynaecological cancers or pre-
vent all sexually transmitted diseases (STDs).
Undecided and opposed mothers justified their pos-
ition by the fact that we have little experience of the vac-
cine to look back on and by fear of side effects with
what is a new vaccine (such reasons were cited by 54.9%
in questionnaires). Some mothers interviewed had in
mind the controversy over a possible link between hepa-
titis B vaccination and multiple sclerosis which affected
France after a mass hepatitis B immunization campaign
among adolescents in 1994. Another 14.1% preferred to
rely on their physician’s decision and waited to know his
opinion, and 7.0% preferred to let their daughters decide
by themselves. The key role played by physicians is il-
lustrated by a mother opposed to the vaccine who ex-
plained in an interview that she did not want to
vaccinate her daughter because her GP was against it:
“He told me not to vaccinate my daughter”. Mothers
from low socio-economic background who were inter-
viewed seemed to adhere totally to their physicians’
opinion while those in higher professional categories
wanted to know his opinion but had a more critical
point of view.
In questionnaires, other concerns mentioned related
to sexual issues: 5.6% found it difficult and too early to
have a discussion about sexuality with their adolescent
daughters, fearing that this might encourage sexual ac-
tivity. Others preferred good gynaecological follow-up
with regular Pap tests (4.5%). The cost of the vaccine
was not mentioned by mothers.
Factors among mothers that appeared to influence their
decision about HPV vaccination
Analysis of factors associated with a favourable versus
undecided/opposed opinion are presented in Table 5. In
the multivariate model, mothers favourable towards the
HPV vaccine were more likely than those who were not
to have already vaccinated their child against pneumo-
coccus. They were more aware of the target population
for HPV vaccination but less knowledgeable about how
frequently women should have Pap test screening. Edu-
cational level, tobacco consumption and history of STDs
were excluded from the final model.
Discussion
One year after the licensing of the HPV vaccine in
France, knowledge about the role of the Pap test in CC
prevention is quite good. However, when asked an open-
ended question about the cause of CC, the link between
HPV and CC was not widely made. Even so, among
mothers of 14–18 year old girls, the majority accepted
Table 5 Factors associated with HPV vaccination acceptance among mothers of 14–18 year old daughters (N=194),






p value Crude OR 95% CI Adjusted OR 95% CI p value
Age1
≥ 40 years old 88 (77.2) 69 (86.3) 0.114 1
< 40 years old 26 (22.8) 11 (13.8) 1.85 0.56-4.01
Employment
Unemployed/Housewife/Retired 24 (18.2) 21 (32.4) 0.640 1
In employment 90 (81.8) 59 (77.6) 1.33 0.68-2.60
Social/financial assistance 5 (4.59) 1 (1.4) 0.234 3.62 0.41-31.59
Family situation
Married/Living with a partner 95 (85.6) 68 (85.0) 0.982 1
Single/Divorced/Widowed 19 (14.4) 12 (15.0) 1.13 0.51-2.48
Vaccination status themselves
Diphtheria-Tetanus-Poliomyelitis and BCG 111 (97.4) 75 (96.1) 0.630 2.47 0.57-10.65
Measles, Mumps and Rubella 41 (37.3) 36 (48.0) 0.339 0.69 0.39-1.24
Hepatitis B 41 (37.3) 31 (41.3) 0.386 0.89 0.49-1.61
Vaccination status of their children
Diphtheria-tetanus-poliomyelitis
and BCG vaccine
113 (99.1) 78 (97.5) 0.367 2.90 0.26-32.54
Measles, Mumps and Rubella 97 (85.1) 65 (81.3) 0.478 1.32 0.62-2.83
Chickenpox 13 (11.4) 7 (8.8) 0.798 1.34 0.51-3.52
Pneumococcus1 27 (23.7) 7 (8.85) 0.007 3.24 1.33-7.86 3.28 1.32-8.11 0.010
Hepatitis B 57 (52.3) 39 (51.4) 0.991 1.05 0.59-1.86
Current smoker1 22 (20.8) 7 (9.09) 0.033 2.62 1.06-6.49
Educational level1
Tertiary 15 (14.3) 17 (24.6) 0.143 1
Upper secondary/non tertiary 35 (33.3) 16 (23.2) 0.051 2.48 0.996-3.99
Primary/lower secondary 55 (52.4) 36 (52.2) 0.185 1.73 0.77-3.90
History of STD1 7 (6.1) 9 (11.2) 0.203 0.52 0.18-1.45
Yearly gynaecological follow up 76 (68.5) 57 (73.1) 0.602 0.81 0.44-1.51
Most recent Pap test within
the past three years
101 (90.2) 67 (84.8) 0.262 1.51 0.66-3.46
“Pap test aims to prevent CC” 76 (66.7) 54 (67.5) 0.903 0.96 0.52-1.76
“Pap test should be
performed during the whole
of adult life” 1
91 (79.8) 73 (91.3) 0.030 0.38 0.15-0.93 0.32 0.12-0.82 0.018
Have heard of HPV vaccine 112 (98.2) 69 (87.3) 0.004 8.12 1.13-38.1
“HPV vaccine is recommended for
young adolescent girls before sexual
debut” or answer close to this” 1
60 (52.6) 30 (37.5) 0.038 1.85 1.03-3.32 2.12 1.15-3.90 0c016
1included in multivariate model, OR, odds ratio, CI, confidence interval, CC, cervical cancer, cpo, sexually transmitted disease.
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undecided.
Responding to multiple choice questions, 93.7% of
women knew that the Pap test should be conducted
yearly or every 2–3 years and 82.0% answered correctly
that screening should continue throughout adult life.
However, only 61% answered that the purpose of Pap
testing is to prevent CC. It seems that women passivelyaccept the Pap test without really knowing why: 80% of
French women are reported to have Pap tests on the ad-
vice of their physician and not on their own initiative
(cervical screening in France is opportunistic.) [24]. Our
data suggest that the cause of CC is not widely known.
Despite information campaigns on CC and its pre-
vention related to the marketing of HPV vaccines, few
respondents (17% of the wider population of women
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HPV. Nevertheless, this level of awareness is much
higher than before introduction of the vaccine: in sur-
veys reported in 2001 and 2004, fewer than 2% of
women mentioned HPV as the cause of CC [25,26].
In contrast, the HPV vaccine itself is now well known:
76% of our overall sample and 91% of mothers had
heard of it. However, they did not know precisely who
should be vaccinated or at which age. This may be
explained by the fact that the predominant source of in-
formation on the vaccine is the media (mentioned by
54.7%). Few women had been individually informed by
their physicians.
The majority of mothers with a 14–18 year old daugh-
ter were supportive of HPV vaccination. A substantial
proportion (38% in our sample) is still undecided, but
very few (< 1%) are clearly opposed. Even if French phy-
sicians have also been shown to be supportive of HPV
vaccination [22], the reality is that in France in 2010,
only 38.7% of 14 year old girls had received at least one
dose of the vaccine. The corresponding uptake among
16 year olds was 50.0%, and among 17 year olds 52.6%.
HPV vaccine acceptance in our sample was lower than
was suggested by data from 2007 when the proportion
of parents intending to vaccinate their child was 67%
[19]. The main issue remains the large population of un-
decided mothers, and we need a better understanding of
factors influencing parental decisions. Protecting one’s
daughter against a potentially lethal cancer is the main
reason mothers give for vaccinating their daughters. Effi-
cacy is not questioned, and the main concern with HPV
immunization is the newness of the vaccine. A year after
the vaccine’s introduction, mothers still feared the emer-
gence of unexpected side effects. Vaccine safety is fre-
quently the main concern about HPV immunization
reported in the literature [10,17,26,27]. In our interviews,
mothers who were still to make up their minds linked
their reluctance to accept the new vaccine to the con-
troversy in France about the suggested connection be-
tween Hepatitis B vaccination and multiple sclerosis [28].
Physicians represent a key influence [29], and their ad-
vice is crucial in avoiding misconceptions among un-
decided mothers [7,17,27]. Freed et al. showed that the
principal information source that mothers trusted was
their physician (76%) [30] and Little et al. found that
mothers who received information from their health care
provider were significantly more likely to intend to vac-
cinate their daughters than those who did not receive
such information (OR=3.56 [1.52-8.45]) [31]. Along with
others, our data suggest that provision by physicians of
more complete information on vaccine safety could en-
courage acceptance [10,13,32]. As a specific example of this,
we found that mothers who knew the target population
for the HPV vaccine were more favourable towards it.We also identified other determinants. Having already
vaccinated their children against pneumococcus was
associated with a positive attitude towards HPV vaccin-
ation. This may reflect a wider attitude towards vaccin-
ation. Mothers who believe vaccines in general are safe
are more willing to vaccinate their daughters against
HPV [10,33-35]. More surprisingly perhaps, our findings
suggested that mothers who did not know how frequent-
ly Pap testing should take place were more favourable
towards HPV vaccination than those with greater know-
ledge. A possible explanation is that women who are
more aware of Pap testing regard it as an effective meth-
od to prevent CC and so see less need for vaccination.
In justifying their position, some mothers unfavourable
to the vaccine argued that an effective method to pre-
vent CC already existed.
However, on multivariate analysis, Pap test adherence
itself was not associated with less acceptance of the
vaccine.
Socio-economic characteristics were not associated
with HPV vaccine acceptance. Unfavourably disposed
mothers did not mention cost as a barrier to vaccination
in either the questionnaire or interviews. This may be
due to the partial reimbursement (65%) by French public
health insurance.
Our results do not support the concern raised previ-
ously that underprivileged populations or populations
with low adherence to Pap test screening would be less
accepting of HPV vaccination. With regard to education-
al level, the results tended to be the reverse, with a lower
acceptance of HPV vaccination among better educated
mothers, as has previously been found [10,11,17,27].
However, two factors found relevant in a recent review
were little mentioned by mothers in our study [19]. Our
respondents did not express the fear that vaccination
would encourage more risky sexual activity, and they did
not reflect a belief that the age for vaccination was too
young [19]. With respect to lack of concern about po-
tential sexual disinhibition, our findings are in line with
those of the recent Canadian study by Ogilvie et al. [28].
And in relation to the age recommended in France for
HPV vaccination, it is worth noting that this is in fact
older than in many countries [36]. Since the median age
at first intercourse in France is 17, many girls aged 14–18
will already have begun sexual activity, while others are
close to doing so.
Possible limitations in our findings should be men-
tioned. Certain factors previously shown to be associated
with HPV vaccine acceptance, such as the younger age
of mothers, STD history, tobacco consumption and edu-
cational level, were significant in univariate analysis but
not after multivariate adjustment. A lack of power due
to the relatively small sample of mothers could explain
these discrepancies. Another limitation is that since
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respondents may have been more attuned than the wider
population to their medical needs. Women included had
a history of good gynaecological follow-up and a high
rate of Pap test screening: 82.9% of the women sampled
(and 87.0% of mothers) had had their most recent Pap
testing within the past three years. Data from the French
public health insurance system estimate that Pap test
coverage nationally is only 56.6% [3]. However in a more
recent study, 79.7% of a sample of 1,688 20–65 year old
women reported having had a Pap test in the past three
years [37], and our sample’s characteristics seem to be
representative of women in the Rhône-Alpes region with
a similar age distribution.
Our choice of question to assess the acceptability of
HPV vaccination, and the multiple choice responses of-
fered, could also be debated. Our intention was to cover
the range of mothers’ attitudes and behaviour. Focus
groups prior to the study showed a good understanding
of this question and of the options for response. More-
over, all respondents were able to justify their opinion
and give further detail in an open ended question; and
those interviewed had additional opportunities to dis-
cuss why they were favourable towards vaccination, or
otherwise.
Finally, we used a cross-sectional design. This did not
allow us to determine whether the associated factors
identified are the cause or the consequence of HPV vac-
cine acceptance: greater knowledge about the vaccine
could be the result of information given during its ad-
ministration or, alternatively, might have driven the deci-
sion to seek vaccination.
One year after French national health authorities
recommended HPV vaccination, knowledge and aware-
ness about HPV as the cause of CC is still poor a
mothers of girls in the targeted age range are globally
favourable towards the HPV vaccine but are seeking
additional information. The results of this study suggest
the type of information that could be disseminated to
improve vaccine uptake. This relates principally to the
record of vaccine safety. However, women do not fully
understand the place of HPV vaccination alongside Pap
testing in CC prevention because they are not fully
aware of HPV as the cause. The need to complete this
link in the information chain could also be addressed.
Appropriate information on these topics may improve
mothers’ acceptance of vaccination for their daughters.
Physicians seem best placed to answer their questions.
Conclusions
Women know that the aim of Pap testing is to prevent
CC; and they know that there is an HPV vaccine. But
they do not know that HPV causes CC. The majority of
mothers of 14–18 year old daughters were favourabletowards HPV vaccination. Those who were unfavourable
justified their opinion mainly by the fear of side effects.
Factors associated with acceptability were knowledge
about the HPV vaccine, acceptance of other vaccines
and lack of knowledge about the recommended fre-
quency of Pap testing. Compliance with recommenda-
tions for Pap test screening and socioeconomic factors
did not significantly affect views on HPV vaccination.
GPs seem to have a key role in providing further infor-
mation about HPV vaccination (particularly in relation
to the virus as the cause of CC) and in reassuring
women of its safety.
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